Guilford: Drug Shows No Major Reversal Of Motor Symptoms
BALTIMORE -(Dow Jones)- Guilford Pharmceuticals Inc. (GLFD) said results from a Phase II clinical trial completed by partner Amgen Inc. (AMGN) showed its drug NIL-A was well-tolerated but didn`t produce a substantial reversal of the motor symptoms of Parkinson`s disease.
Shares of Guilford have plummeted more than 30% on the negative news. The shares recently traded on Nasdaq at $15.21, down $6.79, or 30.9% on heavy volume of 4.9 million shares. Average daily volume is just 257,835 shares.
In a press release Thursday Guilford said the results are based on doses of up to 1000 milligrams of NIL-A taken orally four times a day for six months.
Guilford started Phase II trials in partnership with Amgen about a year ago. The companies are testing neuroimmunophilin ligands in the treatment of Parkinson`s disease.
(This story was originally published by Dow Jones Newswires)
Copyright (c) 2001 Dow Jones & Company, Inc.
All Rights Reserved
|aus der Diskussion:||GUILFORD PHARMACEUTICALS - PART III|
|Autor (Datum des Eintrages):||Maiestro (28.07.01 00:57:46)|
|Beitrag:||49 von 66 (ID:4073550)|
|Alle Angaben ohne Gewähr © wallstreet:online|